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Outline 
1) Modulation of Immune Cells by sunitinib in RCC patients 
2) Sunitinib combined with vaccine in B16.0VA Tumor Model 
3) Suppressive and angiogenic activity of G-MDSC and neutrophils 
4) MDSC role in sunitinib resistance 
Renal Cell Carcinoma (RCC) 
• -50,000 new cases i~ US/year with -13,000 deaths 
• Incidence rising >2.5o/o/year 
• Renal cell carcinoma arising from the renal cortex is responsible for 
80-85% of all kidney cancers. 
• It is an aggressive tumor that often has spread beyond the kidney 
before being diagnosed. 
• Most common histological form of RCC is clear cell (>85o/o) 
• Common to have mutation/inactivation of the VHL tumor suppressor 
gene. 
• Unresponsive to modern chemotherapy or radiotherapy . 
• Anti-angiogenic receptor tyrosine-kinase inhibitors (RTKis) now first-
line therapy 
• sunitinib {Sutent) 
• sorafenib {Nexavar) 
Multitargeted Approaches in mRCC: Sunitinib (Sutent) 
• Small-molecule receptor tyrosine kinase inhibitor1 
• Inhibits all VEGFRs, PDGFR-A, PDGFR-8, c-KIT, and FL T-31 
• Oral administration 1 
• Both antitumor and antiangiogenic activity1 
• FDA approved January 26, 2006 for treatment of advanced RCC2 
• 45°/o response rate in mRCC 
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r-t -Treatment schedule-50mg daily for 4 weeks + 2 weeks off = one cycle 
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Changes in MDSC and MDSC Subpopulations 
Following 1, 2, and 4 Cycles of Sunitinib 
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Reduction in G-MDSC Coincides with Increased T cell IFNy Production 
Pretreatment Levels 
p<0.00005 
Healthy Donor (n=21) RCC Patient (n=55) 






















Pre-Tx Cycle 1 Cycle 2 Cycle 4 
Absolute change in MDSC after 2 cycles of treatment 
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Conclusions: 
1. Sunitinib mediates reversal of MDSC accumulation in peripheral blood of RCC 
patients and enhances T cell IFNy production. 
2. Sunitinib at concentrations achievable in plasma do not inhibit T cell 
proliferation or production of cytokine/chemokines in vitro. 
3. Sunitinib decreases the number of myeloid DC in the peripheral blood. 
4. Sunitinib-mediated MDSC decline in RCC patients was not correlated with 
changes in tumor volume. However, preliminary findings suggest that reduced 
levels of MDSCs after two cycle of therapy was associated with progression-
free survival (p=.005). 
5. Preliminary analysis of tumors from sunitinib treated patients in a neoadjuvant 
setting show variability in MDSC reduction and T cell function. 
6. Pazopanib is also effective at reducing MDSC levels and promoting T cell IFNy 
production. 
Combining Sunitinib with Immunotherapy 
Superior Anti-Tumor Efficacy of Vaccine + TKI Co-Therapy 
M05 (B16.0VA) 
injected s.c. 
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Bose et al. Int. J. Cancer 2011; 129: 2158 - 2170. 
Vaccine/TKI Co-Therapy Promotes the Inhibition of Suppressor Cells 
















Bose et al. Int. J. Cancer 2011; 129: 2158 - 2170. 
Combination Treatment with Vaccine and Sunitinib Improved T cell Response 
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Treatment Cohorts 
Bose et al. Int. J. Cancer 2011; 129: 2158- 2170 
Combination Therapy Results in a Type-1 Biased Immune Profile in the Tumor 
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Bose et al. Int. J. Cancer 2011; 129: 2158 - 2170. 
The Anti-tumor Efficacy of Combined SunitinibNaccine Therapy is CXCR3 
and VCAM-1 Dependent 
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• Sunitinib improves anti-tumor efficacy when combined with 
specific immunization as a combinational therapy. 
• Combinational therapy associated with reductions in MDSC and 
Treg frequencies in the TME 
• Therapeutic benefits correlated with vaccine-induced CDS+ 
TIL frequencies (tetramer) 
Sunitinib Combined with Immunotherapy in Murine Tumor Models 
• Ozao-Choy et. al. J Cancer Res 69:2514, 2009 
4-1 BBLigand/IL 12(adenoviral vector)/sunitinib (MCA26) 
• Bose A et. al. lnt J Cancer 129: 2158, 2010 
OVA-DC vaccine /sunitinib (816-0VA) 
• Farsaci et. al. lnt J Cancer 130:1948, 2012 
Poxvirus-based vaccine (CEA) /sunitinib 
• Kujawski et. al. Cancer Res 70:9599, 2010 
CDB+T cells/sunitinib(Renca) 

















Delta-like 1 homologue 
Preadipocyte factor 1 




Reg. G-protein signaling 5 
Endosialin (CD248) 
Zhao X et al J lmmunol188:1782, 2012 
.Zhao X et al Molecular Therapy 19:805,2011 
Comments 
NOTCH ligand (antagonist) 
EGF Family Member 
Shed by ADAM17/TACE 
Inhibits adipogenesis. 
RTK; binds ephrin A 1, AS 
Involved in angiogenesis, 
migration; poor prognosis 
Expressed by pericyte 
progenitors (from 
hemangioblasts) 
Co-receptor for VEGF/ 
semaphorin 3A; .Involved in 
angiogenesis, axon guidance, 
and cell survival & migration 
Regulates heterotrimeric G 
proteins as a GTPase activator; 
Hypoxia-responsive. 
Binds fibronectin/collagen, 
Role in cell migration 
Overexpression of TBVA Transcripts in Tumor Versus Normal Adjacent 














Ratio of RCC/NAK 
mRNA expression (N = 6) 
Pericyte VEC 
-
0.8 + 0.5 
52.4 + 3.1 5.4 + 1.6 
-
6.5 + 2.6 
37.5 + 4.3 7.6 + 3.2 
1.3 + 0.8 -
8.8 + 3.4 0.6 + 0.5 
13.7 + 4.2 
-
9.5 + 3.2 1.0 + 0.6 
14.6 + 6.1 0.4 + 0.6 
3.5 + 1.1 2.1 + 0.6 
2.7 + 0.7 1.7 + 1.2 
2.2 + 1.0 0.2 + 0.4 
Sunitinib-lnduced Alterations in Type-1 T Cell Response to Vascular 
Antigens in HLA-A2+ RCC Patients (d35 versus dO; IFN-y real-time) 
ThawPBMC 
Place in AIM-V 
Recovery o.n. 37°C 
l 
Add 1 JA.M Peptide 
l 
Culture 2h, 37°C 
l 
Extract mRNA 
Run real-time PCR 
rill W Strokus et al 
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A Randomized Phase II Pilot Trial of Type-1-Polarized Autologous Dendritic Cell Vaccines 
Incorporating TBVA Peptides In Combination With SUNITINIB (SUTENT®) In Patients with 
Metastatic Clear Cell Carcinoma of the Kidney 
HLA-A2+ Therapy-Na"ive Patients 
With Metastatic Clear Cell 
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Vaccine (Wk 1, 3, 5) 
+ Sunitinib 
Cycle 2: 





VAC = aDC1 (1 07) + TBVA Peptide 
Pool (DLK1, EphA2, HBB, NRP1, 
RGS5, TEM1 ), s.c. 
SUT = 50 mg/day 
Primary Endpoint 
• Specific Immune response 
rate in PBMC (MHC/peptide 
dextramers) 
Secondary Endpoints 
• Clinical response rate 
e CDS+ TIL in tumor biopsy 
pre/post 
• Suppressor cell reduction 
tumor/blood 
• Reduction in tumor blood 
vessel density 
• Increased CXCR3 ligand 
chemokine levels in serum 
Suppressive and Angiogenic Activity of G-MDSC in RCC Patients 
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G-MDSC From RCC Patients Relative to Neutrophils Have a 
Significant Population of CD16+1ow population. 
Normal Patient 
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Nude Mouse Xenograft Model of Angiogenesis 
Photograph 
Computer Generated 
Computer Generated By Vessel Diameters 
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. • G-MDSC and neutrophils isolated from are RCC patients are 
. . 1mmunosuppress1ve. 
• Tumor conditioned medium from RCC cell lines can activate neutrophils 
from healthy donors to acquire suppressive activity. 
• This activation causes degranulation of neutrophils with release ofT cell 
suppressive arginase and angiogenic MMP9. 
• Granulocytic MDSC and activated neutrophils may promote increase in 
tumor vasculature. 
• Persistence of MDSC after sunitinib treatment in the tumor may promote 
resistant in some patients and mouse tumor models. 
• Tumor derived products including GM-CSF may protect MDSC from 
sunitinib mediated apoptosis. 
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